Copper Imaging for Pancreatic Cancer

This trial tests a new method for imaging pancreatic cancer using a special compound called Copper Cu 64-DOTA-A2DM in a PET scan. It targets patients with advanced pancreatic cancer that has spread locally or to other parts of the body. The trial aims to determine if this method safely and effectively provides detailed images of cancer cells. Suitable participants have advanced pancreatic cancer that cannot be surgically removed and have had a recent scan showing cancer spread. As a Phase 1 trial, the research seeks to understand how the treatment works in people, offering participants the chance to be among the first to receive this innovative imaging method.

The trial requires that you stop chemotherapy, radiation therapy, biological therapy, or immunotherapy at least 14 days before starting the study treatment. Other medications are not specifically mentioned, so it's best to discuss your current medications with the study team.

Research has shown that using copper-based compounds like Copper Cu 64-DOTA-A2DM for imaging is generally safe. This compound resembles copper Cu 64 dotatate, which the FDA has approved for imaging certain tumors, indicating a reasonable level of safety for similar compounds in humans.

Copper Cu 64 dotatate has been used successfully, with manageable side effects mainly related to radiation exposure. Although there is always a risk of increased radiation exposure, this is common in most imaging procedures using radioactive materials.

Unlike the standard of care for pancreatic cancer, which often involves chemotherapy and radiation, Copper Cu 64-DOTA-A2DM offers a novel approach by using a radioactive copper isotope. This treatment is unique because it integrates a PET scan to track how the drug targets cancer cells, potentially allowing for more precise imaging and assessment. Researchers are excited about this treatment as it could provide a more accurate diagnosis and evaluation of pancreatic cancer, which is crucial for tailoring more effective treatment plans.

Research has shown that Copper Cu 64-DOTA-A2DM, which participants in this trial will receive, can help create clear images of certain cancers, such as pancreatic cancer, when used with PET scans. This compound attaches to areas with high concentrations of a specific protein found in these cancer cells. Studies have demonstrated that similar compounds using copper-64 effectively highlight tumors in imaging tests. For instance, copper-64 has successfully visualized neuroendocrine tumors, providing detailed images that aid in diagnosis. This suggests that Copper Cu 64-DOTA-A2DM might also effectively image pancreatic cancer, helping doctors detect the disease more accurately.¹²⁶⁷⁸